Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 276Lung Neoplasms 106Adenocarcinoma of Lung 28Mesothelioma, Malignant 22Neoplasms 19Neoplasm Metastasis 18Breast Neoplasms 13Brain Neoplasms 13Mesothelioma 10Head and Neck Neoplasms 10Ovarian Neoplasms 8Colorectal Neoplasms 8Recurrence 7Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6NSCLC 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Meningeal Carcinomatosis 5Carcinoma 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Solitary Fibrous Tumor, Pleural 4Sarcoma 4Pancreatic Neoplasms 4Non-small Cell Lung Cancer Metastatic 4Laryngeal Diseases 4Carcinoma, Transitional Cell 4Uterine Neoplasms 3Uterine Cervical Neoplasms 3

Interventions

toripalimab 1camrelizumab 1Pemetrexed 1Drug Therapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non Squamous Non Small Cell Lung Cancer × Pemetrexed × Clear all
NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

CrystalGenomics, Inc.

Phase 2 Recruiting
60 enrolled
Thoracic

Non Squamous Non Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡